Eoflow (294090) Q1 2026 earnings summary

Executive summary

• Specializes in wearable drug delivery solutions, notably disposable insulin pumps (EOPatch), leveraging proprietary low-power, high-performance electro-osmotic pump technology.

• EOPatch is one of only two globally commercialized disposable wearable insulin pumps, with competitive advantages in convenience, performance, and price.

• Expanded into automated insulin delivery (AID) systems and is developing integrated artificial pancreas solutions.

Financial highlights

• Q1 2026 consolidated revenue: KRW 97.9 million, down sharply from KRW 969.8 million in Q1 2025.

• Q1 2026 net loss: KRW 9.10 billion, compared to a net loss of KRW 95.98 billion in Q1 2025.

• Gross profit for Q1 2026: KRW 97.9 million; operating loss: KRW 389.6 million.

• Basic and diluted EPS for Q1 2026: KRW -294 per share.

• Cash and cash equivalents at Q1 2026 end: KRW 1.01 billion, down from KRW 3.45 billion at 2025 year-end.

Outlook and guidance

• Sales decline attributed to ongoing litigation with Insulet, leading to market uncertainty, reduced new user acquisition, and increased user attrition.

• Plans for gradual sales recovery contingent on litigation resolution, user retention, and normalization of global sales activities.